O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert G. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Sandra Goble, Lara Maloney, Jonathan A. Ledermann
Topics & Concepts
MedicineInternal medicinePlaceboClinical endpointOncologyPopulationDiscontinuationRandomized controlled trialEnvironmental healthPathologyAlternative medicinePARP inhibition in cancer therapyAdvancements in Semiconductor Devices and Circuit DesignCalcium signaling and nucleotide metabolism